Briacell Therap (NASDAQ:BCTX) Short Interest Up 84.6% in May

Briacell Therap (NASDAQ:BCTX) saw a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 867,761 shares, an increase of 84.6% from the May 14th total of 470,162 shares. Based on an average trading volume of 269,245 shares, the days-to-cover ratio is presently 3.2 days. Approximately 10.0% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Wall Street Zen raised Briacell Therap from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Briacell Therap presently has an average rating of “Sell”.

Briacell Therap Price Performance

Shares of Briacell Therap stock opened at $2.83 on Wednesday. The stock has a market cap of $24.62 million, a PE ratio of -0.12 and a beta of 1.21. The firm has a fifty day moving average price of $3.76 and a 200 day moving average price of $5.21. Briacell Therap has a 1 year low of $2.60 and a 1 year high of $32.10.

Briacell Therap (NASDAQ:BCTX) last posted its quarterly earnings results on Tuesday, June 9th. The company reported ($0.99) EPS for the quarter.

Hedge Funds Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC purchased a new stake in Briacell Therap (NASDAQ:BCTX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap as of its most recent SEC filing. Institutional investors and hedge funds own 15.42% of the company’s stock.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.